{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:06:19Z","timestamp":1767103579706,"version":"3.48.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,30]]},"DOI":"10.7759\/cureus.100409","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:04:05Z","timestamp":1767103445000},"source":"Crossref","is-referenced-by-count":0,"title":["Intraoperative Detection and Management of Euglycemic Ketonemia During Emergency Surgery Using Point-of-Care Blood Beta-Hydroxybutyrate Testing in a Patient Receiving Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: A Case Report"],"prefix":"10.7759","author":[{"given":"Hiroshi","family":"Takanami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozue","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiyo","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehiro","family":"Masuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Kamibayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo LA","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015, 12:78-89. 10.1177\/1479164114561992","journal-title":"Diab Vasc Dis Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu H","year":"2017","unstructured":"Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017, 33:10.1002\/dmrr.2886","journal-title":"Diabetes Metab Res Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System","volume":"60","author":"Fadini GP","year":"2017","unstructured":"Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017, 60:1385-9. 10.1007\/s00125-017-4301-8","journal-title":"Diabetologia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1721","article-title":"SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications","volume":"41","author":"Meyer EJ","year":"2018","unstructured":"Meyer EJ, Gabb G, Jesudason D. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care. 2018, 41:e47-9. 10.2337\/dc17-1721","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14788","article-title":"The management of diabetic ketoacidosis in adults\u2014an updated guideline from the Joint British Diabetes Society for Inpatient Care","volume":"39","author":"Dhatariya KK","year":"2022","unstructured":"Dhatariya KK. The management of diabetic ketoacidosis in adults\u2014an updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabet Med. 2022, 39:e14788. 10.1111\/dme.14788","journal-title":"Diabet Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock J","year":"2015","unstructured":"Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015, 38:1638-42. 10.2337\/dc15-1380","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/diseases8020014","article-title":"SGLT2 inhibitors: the star in the treatment of type 2 diabetes?","volume":"8","author":"Saisho Y","year":"2020","unstructured":"Saisho Y. SGLT2 inhibitors: the star in the treatment of type 2 diabetes?. Diseases. 2020, 8:10.3390\/diseases8020014","journal-title":"Diseases"},{"key":"ref8","unstructured":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2023). Accessed. March 11, 2024: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros A","year":"2020","unstructured":"Douros A, Lix LM, Fralick M, et al.. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med. 2020, 173:417-25. 10.7326\/M20-0289","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13012","article-title":"Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature","volume":"20","author":"Bonora BM","year":"2018","unstructured":"Bonora BM, Avogaro A, Fadini GP. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab. 2018, 20:25-33. 10.1111\/dom.13012","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi AE","year":"2009","unstructured":"Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009, 32:1335-43. 10.2337\/dc09-9032","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic diabetic ketoacidosis: a review","volume":"13","author":"Modi A","year":"2017","unstructured":"Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2017, 13:315-21. 10.2174\/1573399812666160421121307","journal-title":"Curr Diabetes Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2017.05.004","article-title":"Insights into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: it's not just euglycemic diabetic ketoacidosis","volume":"41","author":"Dizon S","year":"2017","unstructured":"Dizon S, Keely EJ, Malcolm J, Arnaout A. Insights into the recognition and management of SGLT2-inhibitor-associated ketoacidosis: it's not just euglycemic diabetic ketoacidosis. Can J Diabetes. 2017, 41:499-503. 10.1016\/j.jcjd.2017.05.004","journal-title":"Can J Diabetes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-023-03174-8","article-title":"Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports","volume":"37","author":"Seki H","year":"2023","unstructured":"Seki H, Ideno S, Shiga T, et al.. Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports. J Anesth. 2023, 37:465-73. 10.1007\/s00540-023-03174-8","journal-title":"J Anesth"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S122767","article-title":"Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus","volume":"10","author":"Ahmadieh H","year":"2017","unstructured":"Ahmadieh H, Ghazal N, Azar ST. Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus. Diabetes Metab Syndr Obes. 2017, 10:161-7. 10.2147\/DMSO.S122767","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01838","article-title":"Empagliflozin treatment is associated with improved \u03b2-cell function in type 2 diabetes mellitus","volume":"103","author":"Al Jobori H","year":"2018","unstructured":"Al Jobori H, Daniele G, Adams J, et al.. Empagliflozin treatment is associated with improved \u03b2-cell function in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2018, 103:1402-7. 10.1210\/jc.2017-01838","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-010-0926-1","article-title":"Effect of intraoperative acetated Ringer's solution with 1% glucose on glucose and protein metabolism","volume":"24","author":"Yamasaki K","year":"2010","unstructured":"Yamasaki K, Inagaki Y, Mochida S, Funaki K, Takahashi S, Sakamoto S. Effect of intraoperative acetated Ringer's solution with 1% glucose on glucose and protein metabolism. J Anesth. 2010, 24:426-31. 10.1007\/s00540-010-0926-1","journal-title":"J Anesth"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0104","article-title":"The modern role of basal insulin in advancing therapy in people with type 2 diabetes","volume":"48","author":"Bolli GB","year":"2025","unstructured":"Bolli GB, Home PD, Porcellati F, et al.. The modern role of basal insulin in advancing therapy in people with type 2 diabetes. Diabetes Care. 2025, 48:671-81. 10.2337\/dci24-0104","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI102557","article-title":"Studies in fat metabolism. I. The colorimetric determination of ketone bodies in biological fluids","volume":"30","author":"Michaels GD","year":"1951","unstructured":"Michaels GD, Margen S, Liebert G, Kinsell LW. Studies in fat metabolism. I. The colorimetric determination of ketone bodies in biological fluids. J Clin Invest. 1951, 30:1483-5. 10.1172\/JCI102557","journal-title":"J Clin Invest"},{"key":"ref20","unstructured":"Perioperative care of people with diabetes undergoing surgery. (2025). Accessed. March 11, 2024: https:\/\/cpoc.org.uk\/guidelines-and-resources\/guidelines\/guideline-diabetes."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/408268-intraoperative-detection-and-management-of-euglycemic-ketonemia-during-emergency-surgery-using-point-of-care-blood-beta-hydroxybutyrate-testing-in-a-patient-receiving-sodium-glucose-cotransporter-2-sglt2-inhibitors-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T14:04:06Z","timestamp":1767103446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/408268-intraoperative-detection-and-management-of-euglycemic-ketonemia-during-emergency-surgery-using-point-of-care-blood-beta-hydroxybutyrate-testing-in-a-patient-receiving-sodium-glucose-cotransporter-2-sglt2-inhibitors-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.100409","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}